Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer (IBC)

Brief description of study

The purpose of this study is to determine whether the addition of nivolumab to chemotherapy improves response rate in patients with inflammatory breast cancer (IBC). IBC is rare and symptoms are caused by cancer cells blocking lymph vessels in the skin. Symptoms include breast swelling, purple or red color of the skin, and pitting or thickening of the skin of the breast so that it may look and feel like an orange peel. Often, you might not feel a lump, even if it is there. This study will evaluate the safety, efficacy, and tolerability of the combination of nivolumab with neoadjuvant (before surgery) chemotherapy in IBC.


Clinical Study Identifier: s17-00890
ClinicalTrials.gov Identifier: NCT03742986
Principal Investigator: Maryann J Kwa
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.